Normal view MARC view ISBD view

Evolution of novel, low cost, sustainable osteosarcoma care over two decades: Reducing inefficiencies & improving outcomes

In Annals of oncology
By: Bajpai J.
Contributor(s): Mondal T | Simha V | Chandrashekharan A | Hingmire S | Rangarajan B | Shetty N | Shah K | Dusane R | Rekhi B | Vora TS | Ghosh J | Banavali S | Gupta S.
Material type: materialTypeLabelArticlePublisher: 2018Description: .Subject(s): Osteosarcoma | Sarcoma In: Annals of oncology Vol.29, no. Suppl_8, mdy299.031,Summary: Background: Osteosarcoma care is challenging especially in lower and middle income countries with limited resources & increasing patient volumes. We need to reduce inefficient practices &reallocate resources to strategies, which can make the greatest &sustainable improvements in patient care. Methods: We compared the outcomes in non-metastatic osteosarcoma patients treated with 3 sequential non-HDMTX based combination chemotherapy protocols at a single tertiary care center in India over 2 decades. The 1st protocol “OGS-99”, involved dose-intense, alternating doublets of, 4 drugs, doxorubicin(Dox),cisplatin(CDDP),ifosfamide(Ifo) & etoposide(Eto); the 2nd protocol, “OGS-99-enhanced”, involved OGS-99 drugs with enhanced supportive care including growth factors. The 3 rd dose-dense , “OGS-12” protocol, involved administration of 8 sequential doublets of the 3 most active drugs,(Dox, Cis & Ifo), universal growth factor prophylaxis & targeted nutritional support including IV Iron if required . Event free survival (EFS), overall survivals (OS) and toxicity were estimated using retrospective chart review in OGS-99 & OGS-99-enhanced protocols & prospectively in OGS-12 protocol. Results: A total of 41, 94 & 385 treatment naive, consecutive, non-metastatic,extremity patients were treated with OGS-99(year 2000-2005), OGS-99-enhanced (2010) & OGS-12 (2011-2016) respectively. At a median follow-up of 19(3-72), 85(2-99) and 36(6-78) months, the 5 year EFS rates are 36%, 50% and 69% in OGS-99, OGS enhanced & in OGS-12 respectively. The corresponding rates of 5 year OS are non-evaluable, 60% & 83% respectively. OGS-12 protocol fared better with respect to grade ¾ toxicities; febrile neutropenia (40%), thrombocytopenia (36%), anaemia (51%) with 4(1%) chemo toxic deaths & compliance to therapy. Conclusions: Sequential adaption of more rational chemotherapy regimens, including conception of novel "OGS-12" protocol with, better dose density and elimination of ineffective drugs, enhanced supportive care & thereby reducing the need for dose reductions, resulted in marked improvement in outcomes of non-metastatic osteosarcoma patients. This sustainable, economic efficient strategy is worthy of wide adaption
TMC TMH
Tags from this library: No tags from this library for this title. Add tag(s)
Log in to add tags.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode
Articles Articles Tata Memorial Hospital
Available AR19253

Abstract published in the Book of the 43rd ESMO Congress (ESMO 2018) 19–23 October 2018, Munich, Germany


Background: Osteosarcoma care is challenging especially in lower and middle income countries with limited resources & increasing patient volumes. We need to reduce inefficient practices &reallocate resources to strategies, which can make the greatest &sustainable improvements in patient care.

Methods: We compared the outcomes in non-metastatic osteosarcoma patients treated with 3 sequential non-HDMTX based combination chemotherapy protocols at a single tertiary care center in India over 2 decades. The 1st protocol “OGS-99”, involved dose-intense, alternating doublets of, 4 drugs, doxorubicin(Dox),cisplatin(CDDP),ifosfamide(Ifo) & etoposide(Eto); the 2nd protocol, “OGS-99-enhanced”, involved OGS-99 drugs with enhanced supportive care including growth factors. The 3 rd dose-dense , “OGS-12” protocol, involved administration of 8 sequential doublets of the 3 most active drugs,(Dox, Cis & Ifo), universal growth factor prophylaxis & targeted nutritional support including IV Iron if required . Event free survival (EFS), overall survivals (OS) and toxicity were estimated using retrospective chart review in OGS-99 & OGS-99-enhanced protocols & prospectively in OGS-12 protocol.

Results: A total of 41, 94 & 385 treatment naive, consecutive, non-metastatic,extremity patients were treated with OGS-99(year 2000-2005), OGS-99-enhanced (2010) & OGS-12 (2011-2016) respectively. At a median follow-up of 19(3-72), 85(2-99) and 36(6-78) months, the 5 year EFS rates are 36%, 50% and 69% in OGS-99, OGS enhanced & in OGS-12 respectively. The corresponding rates of 5 year OS are non-evaluable, 60% & 83% respectively. OGS-12 protocol fared better with respect to grade ¾ toxicities; febrile neutropenia (40%), thrombocytopenia (36%), anaemia (51%) with 4(1%) chemo toxic deaths & compliance to therapy.

Conclusions: Sequential adaption of more rational chemotherapy regimens, including conception of novel "OGS-12" protocol with, better dose density and elimination of ineffective drugs, enhanced supportive care & thereby reducing the need for dose reductions, resulted in marked improvement in outcomes of non-metastatic osteosarcoma patients. This sustainable, economic efficient strategy is worthy of wide adaption

There are no comments for this item.

Log in to your account to post a comment.

Powered by Koha